TNFRSF9 and B-cell non-Hodgkin lymphoma: Similarly, normal PBMCs co-cultured with rituximab-opsonised Ramos B-cell lymphoma cells resulted in the upregulation of CD134 on NK cells, albeit to a lesser extent compared to CD137 (22% vs 61% positive NK cells respectively) (Fig. 2A).